08/21/14 - 10:23 AM EDT
Ampio Pharmaceuticals is blaming a mini Polar Vortex for blowing up a pivotal study of its osteoarthritis drug Ampion.READ FULL POST
08/14/14 - 10:20 AM EDT
Contradictory statements made on whether or not Northwest Bio conducted an interim analysis of its DC-Vax phase III study.READ FULL POST
08/13/14 - 12:04 PM EDT
Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.READ FULL POST
08/12/14 - 05:11 PM EDT
The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.READ FULL POST
08/12/14 - 07:17 AM EDT
The struggling Provenge peddler is suffocating under $620 million in debt and the bill comes soon.READ FULL POST
08/11/14 - 05:29 PM EDT
Intercept's OCA data look good. I don't see anything in the study results which scream, "RUN AWAY!" This is what some investors feared, causing the stock price to fall recently.READ FULL POST
08/06/14 - 12:07 PM EDT
By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer.READ FULL POST
08/04/14 - 10:07 AM EDT
CNN reports competing, secret Ebola therapy already saved lives of U.S. aid workers.READ FULL POST
08/01/14 - 11:11 AM EDT
In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.READ FULL POST
07/29/14 - 10:26 AM EDT
Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.